Literature DB >> 16807412

Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer.

Rebecca A Barnetson1, Albert Tenesa, Susan M Farrington, Iain D Nicholl, Roseanne Cetnarskyj, Mary E Porteous, Harry Campbell, Malcolm G Dunlop.   

Abstract

BACKGROUND: The identification of mutations in germ-line DNA mismatch-repair genes at the time of diagnosis of colorectal cancer is important in the management of the disease.
METHODS: Without preselection and regardless of family history, we recruited 870 patients under the age of 55 years soon after they received a diagnosis of colorectal cancer. We studied these patients for germ-line mutations in the DNA mismatch-repair genes MLH1, MSH2, and MSH6 and developed a two-stage model by multivariate logistic regression for the prediction of the presence of mutations in these genes. Stage 1 of the model incorporated only clinical variables; stage 2 comprised analysis of the tumor by immunohistochemical staining and tests for microsatellite instability. The model was validated in an independent population of patients. We analyzed 2938 patient-years of follow-up to determine whether genotype influenced survival.
RESULTS: There were 38 mutations among the 870 participants (4 percent): 15 mutations in MLH1, 16 in MSH2, and 7 in MSH6. Carrier frequencies in men (6 percent) and women (3 percent) differed significantly (P<0.04). The addition of immunohistochemical analysis in stage 2 of the model had a sensitivity of 62 percent and a positive predictive value of 80 percent. There were 35 mutations in the validation series of 155 patients (23 percent): 19 mutations in MLH1, 13 in MSH2, and 3 in MSH6. The performance of the model was robust among a wide range of cutoff probabilities and was superior to that of the Bethesda and Amsterdam criteria for hereditary nonpolyposis colorectal cancer. Survival among carriers was not significantly different from that among noncarriers.
CONCLUSIONS: We devised and validated a method of identifying patients with colorectal cancer who are carriers of mutations in DNA repair genes. Survival was similar among carriers and noncarriers. Copyright 2006 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16807412     DOI: 10.1056/NEJMoa053493

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  145 in total

1.  MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer.

Authors:  María Dolores Giráldez; Francesc Balaguer; Luis Bujanda; Miriam Cuatrecasas; Jenifer Muñoz; Virginia Alonso-Espinaco; Mikel Larzabal; Anna Petit; Victoria Gonzalo; Teresa Ocaña; Leticia Moreira; José María Enríquez-Navascués; C Richard Boland; Ajay Goel; Antoni Castells; Sergi Castellví-Bel
Journal:  Clin Cancer Res       Date:  2010-10-05       Impact factor: 12.531

Review 2.  Lynch syndrome diagnostics: decision-making process for germ-line testing.

Authors:  E Lastra; M García-González; B Llorente; C Bernuy; M J Barrio; L Pérez-Cabornero; M Durán; C García-Girón
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

Review 3.  Microsatellite instability in colorectal cancer.

Authors:  C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

4.  Report of the combined meeting of the International Society for Gastrointestinal Hereditary Tumours, the Human Variome Project and the National Cancer Institute Colon Cancer Family Registry, Duesseldorf, Germany, 24 June 2009.

Authors:  Maija Kohonen-Corish; Thomas K Weber; Annika Lindblom; Finlay Macrae
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

5.  The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history.

Authors:  Fay Kastrinos; Ewout W Steyerberg; Rowena Mercado; Judith Balmaña; Spring Holter; Steven Gallinger; Kimberly D Siegmund; James M Church; Mark A Jenkins; Noralane M Lindor; Stephen N Thibodeau; Lynn Anne Burbidge; Richard J Wenstrup; Sapna Syngal
Journal:  Gastroenterology       Date:  2010-08-19       Impact factor: 22.682

6.  Bethesda criteria for microsatellite instability testing: impact on the detection of new cases of Lynch syndrome.

Authors:  Miguel Serrano; Pedro Lage; Sara Belga; Bruno Filipe; Inês Francisco; Paula Rodrigues; Ricardo Fonseca; Paula Chaves; Isabel Claro; Cristina Albuquerque; António Dias Pereira
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

7.  Inherited colorectal cancer syndromes.

Authors:  Robert Gryfe
Journal:  Clin Colon Rectal Surg       Date:  2009-11

8.  A genome-wide gene-gene interaction analysis identifies an epistatic gene pair for lung cancer susceptibility in Han Chinese.

Authors:  Minjie Chu; Ruyang Zhang; Yang Zhao; Chen Wu; Huan Guo; Baosen Zhou; Jiachun Lu; Yongyong Shi; Juncheng Dai; Guangfu Jin; Hongxia Ma; Jing Dong; Yongyue Wei; Cheng Wang; Jianhang Gong; Chongqi Sun; Meng Zhu; Yongyong Qiu; Tangchun Wu; Zhibin Hu; Dongxin Lin; Hongbing Shen; Feng Chen
Journal:  Carcinogenesis       Date:  2013-12-09       Impact factor: 4.944

9.  Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer.

Authors:  Amanda S Bruegl; Bojana Djordjevic; Brittany Batte; Molly Daniels; Bryan Fellman; Diana Urbauer; Rajyalakshmi Luthra; Charlotte Sun; Karen H Lu; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2014-04-25

10.  Cancer risks for MLH1 and MSH2 mutation carriers.

Authors:  James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins
Journal:  Hum Mutat       Date:  2013-03       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.